NHS Digital announces patient de-identification software partnership

NHS Digital announces patient de-identification software partnership

July 5 2018 NHS Digital will introduce new software for the de-identification of patient...

Over half of acute trusts are now using GP e-Referral Service

Over half of acute trusts are now using GP e-Referral Service

June 14 2018 More than 50% of acute hospital trusts in England have switched off paper referrals...

NEWS app for sepsis scoring available

NEWS app for sepsis scoring available

June 4 2018 An app has been re-launched to help clinicians staff across NHS Wales calculate an...

NHS launches National Data Opt-Out facility

NHS launches National Data Opt-Out facility

May 31 2018 NHS patients can formally opt out of having their data used for research or planning...

ePACT to be decommissioned on June 8 as ePACT2 takes over

ePACT to be decommissioned on June 8 as ePACT2 takes over

May 29 2018 NHS Business Services Authority will decommission ePACT with effect from June 8, as...

  • NHS Digital announces patient de-identification software partnership

    NHS Digital announces patient de-identification software partnership

    Thursday, 05 July 2018 16:48
  • Over half of acute trusts are now using GP e-Referral Service

    Over half of acute trusts are now using GP e-Referral Service

    Thursday, 14 June 2018 14:29
  • NEWS app for sepsis scoring available

    NEWS app for sepsis scoring available

    Monday, 04 June 2018 09:58
  • NHS launches National Data Opt-Out facility

    NHS launches National Data Opt-Out facility

    Thursday, 31 May 2018 09:01
  • ePACT to be decommissioned on June 8 as ePACT2 takes over

    ePACT to be decommissioned on June 8 as ePACT2 takes over

    Tuesday, 29 May 2018 12:48

a doctor in consultation imageFebruary 9 2018

Precautions around the use of dopaminergic drugs in Parkinson’s disease are included in a new NICE Quality Standard. 


One of the five quality statements in QS 164 says that patients receiving dopaminergic therapy should be given advice about the risk of developing impulse control disorders. The quality statement has been included as “dopaminergic therapy, especially with dopamine agonists, is associated with a risk of developing impulse control disorders,” says NICE.

“It is important to discuss this risk and provide information to adults with Parkinson's disease, and their family members and carers, when starting treatment and at least annually. This will help them to recognise the symptoms and know where to get help if these develop.”

NICE expects healthcare professionals to “provide oral and written information about the risk of developing impulse control disorders to adults with Parkinson's disease when starting dopaminergic therapy (not just dopamine agonists) and discuss this with them at least annually.” They should also provide information for family members and carers if appropriate.

In addition, “oral and written information should be given about:

  • the different types of impulse control disorders (for example, compulsive gambling, hypersexuality, binge eating and obsessive shopping);
  • the increased risk of impulse control disorders developing with dopamine agonists;
  • the risk that impulse control disorders may be concealed by the person affected;
  • who to contact if impulse control disorders develop;
  • the possibility that if problematic impulse control disorders develop, dopamine agonist therapy will be reviewed and may be reduced or stopped.”

A sperate quality statement says that patients should have a point of contact with specialist services. They should also be “referred to physiotherapy, occupational therapy or speech and language therapy if they have problems with balance, motor function, activities of daily living, communication, swallowing or saliva.”

This means GPs and others need to be “aware of local referral pathways to physiotherapy, occupational therapy and speech and language therapy for adults with Parkinson’s disease.” Healthcare professionals should “carry out regular assessments of balance, motor function, activities of daily living, communication, swallowing and saliva for adults with Parkinson’s disease and refer them for physiotherapy, occupational therapy or speech and language therapy specific for Parkinson’s disease if problems are identified.”

A further quality statement says patients should have access to clozapine and patient monitoring for treating hallucinations and delusions.

The Quality Standards should be used alongside NICE guideline NG71 on Parkinson’s disease in adults.

Links:
NICE QS 164 Parkinson’s Disease           
NICE Guideline on Parkinson’s disease in adults NG71   

Management News

July 27 2018 Adolescent boys will be offered the human papilloma virus (HPV) vaccine to protect them from cancer, the Department of Health and Social Care has announced.
July 20 2018 Doctors are being reminded to ensure that any patient or other records which may be relevant to the UK Infected Blood Inquiry are not destroyed. Earlier this month, the Inquiry’s Chair, Sir...